2. Metabolic Enzyme/Protease Immunology/Inflammation
  3. Phosphodiesterase (PDE) Interleukin Related
  4. PDE3/4-IN-4

PDE3/4-IN-4 is an orally active PDE3A and PDE4B inhibitor with IC50 values of 10 nM and 9.4 nM, respectively. PDE3/4-IN-4 shows selective activity relative to most other PDE family members. PDE3/4-IN-4 modulates the cAMP/PKA/CREB signaling pathway. PDE3/4-IN-4 inhibits pro-inflammatory factor IL-6. PDE3/4-IN-4 reduces expression of inflammatory markers in liver tissue. PDE3/4-IN-4 attenuates liver fibrosis. PDE3/4-IN-4 limits liver damage in cholestatic and sepsis-induced liver disease mice models. PDE3/4-IN-4 can be used for the research of liver injury, cholestatic liver diseases, sepsis-induced liver injury.

For research use only. We do not sell to patients.

PDE3/4-IN-4

PDE3/4-IN-4 Chemical Structure

CAS No. : 3088024-27-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

PDE3/4-IN-4 Related Antibodies

Top Publications Citing Use of Products

View All Phosphodiesterase (PDE) Isoform Specific Products:

View All Isoforms
PDE1 PDE2 PDE3 PDE4 PDE5 PDE6 PDE7 PDE9 PDE10 PDE11 PDE12 PDE8 Autotaxin

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PDE3/4-IN-4 is an orally active PDE3A and PDE4B inhibitor with IC50 values of 10 nM and 9.4 nM, respectively. PDE3/4-IN-4 shows selective activity relative to most other PDE family members. PDE3/4-IN-4 modulates the cAMP/PKA/CREB signaling pathway. PDE3/4-IN-4 inhibits pro-inflammatory factor IL-6. PDE3/4-IN-4 reduces expression of inflammatory markers in liver tissue. PDE3/4-IN-4 attenuates liver fibrosis. PDE3/4-IN-4 limits liver damage in cholestatic and sepsis-induced liver disease mice models. PDE3/4-IN-4 can be used for the research of liver injury, cholestatic liver diseases, sepsis-induced liver injury[1].

IC50 & Target[1]

PDE3A

10 nM (IC50)

PDE4B

9.4 nM (IC50)

PDE10A

477.9 nM (IC50)

PDE6C

5739 nM (IC50)

PDE1A

>10000 nM (IC50)

PDE2A

>10000 nM (IC50)

PDE5A

>10000 nM (IC50)

PDE7A

>10000 nM (IC50)

PDE8A

>10000 nM (IC50)

PDE11A

>10000 nM (IC50)

IL-6

 

In Vitro

PDE3/4-IN-4 (compound D5) (10-60 μM; 24 h) does not exhibit significant toxicity in LO2 human normal liver cells at concentrations up to 60 μM after 24 h treatment[1].
PDE3/4-IN-4 (compound D5) inhibits IL-6 secretion in Lipopolysaccharides (LPS) (HY-D1056)-stimulated LO2 cells with an IC50 of 14.89 μM[1].
PDE3/4-IN-4 (compound D5) (15 μM; 12 h pre-treatment before 4 h LPS stimulation) increases p-CREB and p-PKA expression in LPS-induced LO2 cells[1].
PDE3/4-IN-4 (compound D5) possesses adequate metabolic stability in mouse, rat, dog, monkey, and human liver microsomes[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PDE3/4-IN-4 Related Antibodies

Western Blot Analysis[1]

Cell Line: LPS-induced LO2 cells
Concentration: 15 μM (pre-treatment before LPS stimulation)
Incubation Time: 12 h (pre-treatment before 4 h LPS stimulation)
Result: Markedly increased the expression of phosphorylated CREB (p-CREB) and phosphorylated PKA (p-PKA) compared to LPS-induced cells; confirmed increased p-CREB expression via immunofluorescence staining.
Parmacokinetics
Species Dose Route AUC0-t AUC0-∞ Cmax T1/2 Tmax F C0 Vz CL
Mice[1] 5 mg/kg i.v. 13909.7 ng·h/mL 13931.6 ng·h/mL / 2.134 h / / 18302.0 ng/mL 1122.9 mL/kg 370.0 mL/h/kg
Mice[1] 10 mg/kg p.o. 3479.9 ng·h/mL 3489.3 ng·h/mL 922.4 ng/mL 1.4 h 1.0 h 12.5 % / / /
In Vivo

PDE3/4-IN-4 (compound D5) (10-40 mg/kg; p.o.; daily; 7 days) reduces hepatic inflammation and fibrosis in bile duct ligation (BDL) mice, with 40 mg/kg being more effective[1].
PDE3/4-IN-4 (10-40 mg/kg; p.o.; daily; 7 days) reduces hepatic inflammation and injury in cecal ligation and puncture (CLP) mice, with 40 mg/kg being more effective[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 (male, 18-22 g, bile duct ligation surgery)[1]
Dosage: 10 mg/kg; 40 mg/kg
Administration: p.o.; daily; 7 days
Result: Significantly reduced hepatic mRNA expression of IL-6 and IL-1β; reduced total bile acid (TBA) and alanine aminotransferase (ALT) levels; partially restored liver architecture (HE staining); increased hepatic p-CREB and p-PKA expression; reduced collagen deposition (Masson staining, 40 mg/kg only); showed greater efficacy at 40 mg/kg.
Animal Model: C57BL/6 (male, 18-22 g, cecal ligation and puncture surgery)[1]
Dosage: 10 mg/kg; 40 mg/kg
Administration: p.o.; daily; 7 days
Result: Reduced hepatic mRNA expression of IL-6 and IL-1β; reduced total bile acid (TBA), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels; increased hepatic p-CREB and p-PKA expression; reduced hepatic inflammatory cell infiltration and restored hepatocyte structure (HE staining, 40 mg/kg only); reduced collagen deposition (Masson staining, 40 mg/kg only); showed greater efficacy at 40 mg/kg.
Molecular Weight

559.56

Formula

C30H27F2N5O4
CAS No.
SMILES

CC1CC(NN=C1C2=CC=C(C=C2)NC(C3=CC=CC4=C3N=C(N4)C5=CC(OCC6CC6)=C(C=C5)OC(F)F)=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

PDE3/4-IN-4 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PDE3/4-IN-43088024-27-2Phosphodiesterase (PDE)Interleukin RelatedILliver tissueIL-6cholestatic liver diseasesliver microsomescAMP/PKA/CREB signaling pathwayLO2 human normal liver cellsPDE3Asepsis-induced liver injuryPDE4Bliver fibrosisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PDE3/4-IN-4
Cat. No.:
HY-181088
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.